Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Operating Expenses: 2009-2025

Historic Operating Expenses for Cumberland Pharmaceuticals (CPIX) over the last 17 years, with Sep 2025 value amounting to $10.3 million.

  • Cumberland Pharmaceuticals' Operating Expenses fell 4.85% to $10.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $44.5 million, marking a year-over-year decrease of 6.34%. This contributed to the annual value of $44.3 million for FY2024, which is 9.79% down from last year.
  • Latest data reveals that Cumberland Pharmaceuticals reported Operating Expenses of $10.3 million as of Q3 2025, which was down 11.46% from $11.6 million recorded in Q2 2025.
  • Cumberland Pharmaceuticals' Operating Expenses' 5-year high stood at $15.5 million during Q4 2023, with a 5-year trough of $9.6 million in Q3 2021.
  • For the 3-year period, Cumberland Pharmaceuticals' Operating Expenses averaged around $11.4 million, with its median value being $10.9 million (2023).
  • Per our database at Business Quant, Cumberland Pharmaceuticals' Operating Expenses skyrocketed by 36.23% in 2023 and then declined by 20.95% in 2024.
  • Quarterly analysis of 5 years shows Cumberland Pharmaceuticals' Operating Expenses stood at $12.7 million in 2021, then decreased by 10.04% to $11.4 million in 2022, then spiked by 36.23% to $15.5 million in 2023, then decreased by 20.95% to $12.3 million in 2024, then declined by 4.85% to $10.3 million in 2025.
  • Its Operating Expenses was $10.3 million in Q3 2025, compared to $11.6 million in Q2 2025 and $10.4 million in Q1 2025.